RT Journal Article
SR Electronic
T1 Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.10.20150540
DO 10.1101/2020.07.10.20150540
A1 Sweeney, Nicola
A1 Merrick, Blair
A1 Galão, Rui Pedro
A1 Pickering, Suzanne
A1 Botros, Alina
A1 Wilson, Harry
A1 Signell, Adrian W
A1 Betancor, Gilberto
A1 Tan, Mark Kia Ik
A1 Ramble, John
A1 Kouphou, Neophytos
A1 Acors, Sam
A1 Graham, Carl
A1 Seow, Jeffrey
A1 MacMahon, Eithne
A1 Neil, Stuart JD
A1 Malim, Michael H
A1 Doores, Katie
A1 Douthwaite, Sam
A1 Batra, Rahul
A1 Nebbia, Gaia
A1 Edgeworth, Jonathan D
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.10.20150540.abstract
AB OBJECTIVE Determine indications and clinical utility of SARS-CoV-2 serology testing in adults and children.DESIGN Prospective evaluation of initial three weeks of a daily Monday to Friday pilot SARS-CoV-2 serology service for patients.SETTING Early post “first-wave” SARS-CoV-2 transmission period at single centre London teaching hospital that provides care to the local community, as well as regional and national referral pathways for specialist services.PARTICIPANTS 110 (72 adults, 38 children, age range 0-83 years, 52.7% female (n=58)).INTERVENTIONS Patient serum from vetted referrals tested on CE marked and internally validated lateral flow immunoassay (LFIA) (SureScreen Diagnostics) detecting antibodies to SARS-CoV-2 spike proteins, with result and clinical interpretation provided to the direct care team.MAIN OUTCOME MEASURES Performance characteristics, source and nature of referrals, feasibility and clinical utility of the service, particularly the benefit for clinical decision-making.RESULTS The LFIA was deemed suitable for clinical advice and decision making following evaluation with 310 serum samples from SARS-CoV-2 PCR positive patients and 300 pre-pandemic samples, giving a sensitivity and specificity of 96.1% and 99.3% respectively. For the pilot, 115 referrals were received leading to 113 tests performed on 108 participants (sample not available for two participants); paediatrics (n=35), medicine (n=69), surgery (n=2) and general practice (n=2). 43.4% participants (n=49) had detectable antibodies to SARS-CoV-2. There were three main indications for serology; new acute presentations potentially triggered by recent COVID-19 infection e.g. PIMS-TS (n=26) and pulmonary embolism (n=5), potential missed diagnoses in context of a recent compatible illness (n=40), and making infection control and immunosuppression treatment decisions in persistently SARS-CoV-2 RNA PCR positive individuals (n=6).CONCLUSIONS This study shows acceptable performance characteristics, feasibility and clinical utility of a SARS-CoV-2 serology service using a rapid, inexpensive and portable assay for adults and children presenting with a range of clinical indications. Results correlated closely with a confirmatory in-house ELISA. The study showed the benefit of introducing a serology service where there is a reasonable pre-test probability, and the result can be linked with clinical advice or intervention. Experience thus far is that the volume of requests from hospital referral routes are manageable within existing clinical and laboratory services; however, the demand from community referrals has not yet been assessed. Given recent evidence for a rapid decline in antibodies, particularly following mild infection, there is likely a limited window of opportunity to realise the benefit of serology testing for individuals infected during the “first-wave” before they potentially fall below a measurable threshold. Rapidly expanding availability of serology services for NHS patients will also help understand the long-term implications of serostatus and prior infection in different patient groups, particularly before emergence of any “second-wave” outbreak or introduction of a vaccination programme.WHAT IS ALREADY KNOWN ON THIS TOPIC The mechanisms and utility of providing a SARS-CoV-2 (COVID-19) serology service is under evaluation. There are different technologies detecting antibodies against different SARS-CoV-2 proteins. Antibodies are known to appear from about 10 days after symptom onset but it is unclear how long they persist.WHAT THIS STUDY ADDS A SARS-CoV-2 serology service using a validated lateral flow immunoassay measuring antibodies against spike protein can be rapidly introduced with clinical benefit demonstrated for a broad range of individuals. Indications include ‘missed’ diagnoses where COVID-19 infection has been suspected but SARS-COV-2 RNA tests were either negative or not performed, conditions potentially triggered by COVID-19 such as pulmonary embolism, and predicting infectivity or immunity in patients with persistently detectable SARS-CoV-2 RNA. Testing is quick, simple to perform and inexpensive, however emerging evidence that antibodies fall rapidly particularly in mild disease, and the observed breadth of emerging indications highlight the urgent need for targeted testing with clinical interpretation provided on a case-by-case basis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKings Together Rapid COVID-19 Call awards to KJD, SJDN and RMN. MRC Discovery Award MC/PC/15068 to SJDN, KJD and MHM. National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas NHS Foundation Trust and King's College London, programme of Infection and Immunity (RJ112/N027) to MHM and JE AWS and CG were supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). GB was supported by the Wellcome Trust (106223/Z/14/Z to MHM). SA was supported by an MRC-KCL Doctoral Training Partnership in Biomedical Sciences industrial Collaborative Award in Science & Engineering (iCASE) in partnership with Orchard Therapeutics (MR/R015643/1). NK was supported by the Medical Research Council (MR/S023747/1 to MHM). SP, HDW and SJDN were supported by a Wellcome Trust Senior Fellowship (WT098049AIA). Fondation Dormeur, Vaduz for funding equipment (KJD). Development of SARS-CoV-2 reagents (RBD) was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was performed in accordance with the UK Policy Framework for Health and Social Care Research, and approved by the Risk and Assurance Committee at Guy's and St Thomas' NHS Foundation Trust. Informed consents were not required from participants in this study as per the guidelines set out in the UK Policy Framework for Health and Social Care Research and by the registration with and express consent of the Institutional Review Board listed above.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data will be available, upon request, from corresponding author.